Navigation Links
NIH Announces Advanced Cell Technology's 'Single Cell Embryo Biopsy Technique' as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
Date:9/20/2007

referred to ACT's Nature article in its implementation plan. In June of this year, ACT announced that it had successfully produced 4 human embryonic stem cell lines without destroying the embryos at its lab in Worcester, Massachusetts. The embryo from which the cell was removed remains cryogenically preserved and remains a viable embryo. Should the company's blastomere technique satisfy NIH qualifications, ACT could qualify for federal funding from the NIH.

"Our single cell blastomere technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the order, is available today. We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available and hope they will consider our technique for federal funding," remarked William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit http://www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including sta
'/>"/>

SOURCE Advanced Cell Technology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...s release is available in German . , Whethe...cards: RFID tags (Radio Frequency Identification) ...ife. They make it possible to label objects or goo...ncy. The appropriate scanner can read and process ...be affixed to goods under production conditions of...
(Date:11/24/2009)... The New York investment bank K...X:NEU) has agreed an AU$6.7 mil convertible note p...r. The private placement was arranged by KTA Capit...or. , New York (PRWEB) No...ment bank KTA Capital, LLC ("KTA Capital"...
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novembe...c. (Nasdaq: DCGN ) today announced that it has rec...ding in the company,s common stock will be,suspend...be filed with the,Securities and Exchange Commissi...isting on Nasdaq, unless the company files an appe...
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novembe...c. (Nasdaq: DCGN ) today announced the approval of...ptcy Court for the District of Delaware,(the "Bank... petition for,relief under Chapter 11 of the Unite.... , The orders issued by the Bankruptcy C...
Breaking Biology Technology:Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
...swire-FirstCall/ - Ondine Biopharma,Corporation (T...eveloping,photodisinfection-based products, today ...n in the Treatment of Chronic Periodontitis" will ...rican Academy of,Periodontology,s (AAP) annual mee... Washington State Convention and Trade Center in S...
...ampbell Alliance, the leading,management consultin...ech,industry, today announced that leaders from it...ents at the Center for Business Intelligence,s (CB...Model, to be held September,8 and 9, 2008, at the ...inning sales professional before becoming a pharma...
...4 BioForm Medical,Inc. (Nasdaq: BFRM ) today ann...r and full fiscal year ended June 30, 2008. Net sa...30, 2008 as compared to $15.4 million,for the quar...on or 8.4%.,The net loss was $20.0 million for the...loss of $4.9 million for the quarter ended June 30...
Other Biology Technology:Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontology's 94th Annual Meeting 2Campbell Alliance Sales Practice to Present at CBI's Leadership Summit on Evolving the Pharma Sales Model 2Campbell Alliance Sales Practice to Present at CBI's Leadership Summit on Evolving the Pharma Sales Model 3Campbell Alliance Sales Practice to Present at CBI's Leadership Summit on Evolving the Pharma Sales Model 4BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 3BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 4BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 5BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 6BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 7BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 8BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 9
(Date:11/25/2009)..., LA JOLLA, CAWhen you eat may be just as vital t...t the Salk Institute for Biological Studies. Their...g and waning of thousands of genes in the liverthe...d by food intake and not by the body,s circadian c...ng time determines the activity of a large number ...
(Date:11/24/2009)... Scientists have crystallised a protein that may h...t. The protein could be used by probiotic producer...l benefit to people. , "Probiotics need to intera...effect, and if they attach to surfaces in the gut ...o exert their activity," says Dr Nathalie Juge fro...
(Date:11/24/2009)..., NEW YORK (November 24, 2009) -- T...oday a report revealing that the last remaining po...gnificantly due to the rising tide of poaching and... will help inform Russian officials of what needs ... world,s biggest cat. , The report ...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A sticky solution for identifying effective probiotics 2Report shows dramatic decline in Siberian tigers 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 1Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 9GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 1GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 2GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 3Opto electronic nose sniffs out toxic gases 9902 1Opto electronic nose sniffs out toxic gases 9902 2Opto electronic nose sniffs out toxic gases 9902 3
...neers who study both flow hydrodynamics and how ba...r the high incidence of infections associated with...athogenic bacteria swim "to the left," in a study ...chia coli (E. coli) and some other pathogenic bact...d when they are near a surface," said Hür Köser ,...
...s extracted from a marine seaweed may protect agai...ch suggests. , The animal study indicates that ch...ch are found in a type of brown marine seaweed, mi...olet B (UVB) radiation. , UVB radiation in sun... estimated 1.3 million cases of non-melanoma skin ...
...en , professor of molecular biophysics and bioche... the Prostate Cancer Foundation to expand research...e cancer using nanoparticles. , Garen and his c...ctly target and destroy the blood vessels of solid...normal tissue unharmed. , The technology uses ...
Other Biology News:Swimming 'to the left' gets bacteria upstream, and may promote infection 2Chemicals in brown algae may protect against skin cancer 2Nanoparticles for delivery of prostate cancer treatment 2
S-Protein Agarose from Novagen
Blasticidin S HCl from Invitrogen
15(S)-15-methyl Prostaglandin F2alpha from Cayman Chemical
...ns who function to ensure the integrity of the DNA...ading the nascent strands in DNA ,replication, in ...nd in preventing chromosomal recombination between... specifically at base pair mismatches and small (<...
Biology Products: